62
Participants
Start Date
April 21, 2021
Primary Completion Date
December 1, 2022
Study Completion Date
December 1, 2022
PT01 (Pegtomarginase)
PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing. Normal cells can continue to make their own arginine inside the cell, so PT01 targets the rapidly growing cancer cells.
RECRUITING
Mayo Clinic, Jacksonville
RECRUITING
Mayo Clinic, Rochester
RECRUITING
Mayo Clinic, Phoenix
Lead Sponsor
Athenex, Inc.
INDUSTRY